Sunday, May 18, 2014

Thorasys at ATS 2014

Today was the beginning of the exhibition at ATS 2014. We met many new people and reunited with some dear friends. A big thanks to everyone who stopped by and shared their passion for effortless lung function measurements with us. For those who have not yet had the chance to see us in person, please stop by booth 4125 at either:
·         Monday May 19th, 10:30am-3:00pm
·         Tuesday May 20th, 10:30am-3:00pm

Warms regards,

Your Thorasys team


Thursday, May 15, 2014

tremoFlo Airwave Oscillometry System at ATS 2014

Join us at ATS 2014 in San Diego this coming weekend! We invite you to visit us in the exhibit hall at Booth 4125 for a demonstration of the tremoFlo C-100 Airwave Oscillometry System (AOS). The exhibit will be open as follows:

  • Sunday, May 18, 10:30 am to 4 pm
  • Monday, May 19, 10:30 am to 3 pm
  • Tuesday, May 20, 10:30 am to 3 pm

We look forward to seeing you!

Your THORASYS Team




Tuesday, May 6, 2014

World Asthma Day


Tuesday, May 6th is World Asthma Day, an annual event organized by the Global Initiative for Asthma (GINA). The theme for this year’s World Asthma Day is “You Can Control Your Asthma”, designed to raise awareness and care for asthma around the world.


To learn more about World Asthma Day, please visit the Global Initiative for Asthma at: http://www.ginasthma.org/World-Asthma-Day

Tuesday, February 25, 2014

Newly TGA-certified tremoFlo™ C-100 on display at TSANZSRS

The tremoFlo Airwave Oscillometry System continues to break ground in markets around the world. Only a few weeks after approval in Europe and Canada, we have earned approval by the Australian Therapeutic Goods Administration (TGA), so that the tremoFlo is now available for diagnostic and clinical use in Australia.

“I very much want to thank our team for their great work and enthusiasm as they continue to execute our regulatory strategy on or even ahead of schedule” says Dr. Thomas Schuessler, President and CEO of THORASYS. “Australia is known to excel in pulmonary research and medicine, and we are happy to serve this knowledgeable customer base.”


The tremoFlo Airwave Oscillometry System will be on display at the joint Thoracic Society of Australia and New Zealand and Australia and New Zealands Society for Respiratory Science (TSANZRS) conference on April 4-9 in Adelaide. Come visit us at the BIRD Healthcare booth within the exhibition hall. We hope to see you there!

[ Ask a Question | View TGA Certificate | Follow us on Twitter |
Connect on LinkedIn ]

Friday, February 7, 2014

tremoFlo™ C-100 is now Health Canada approved!

The entire THORASYS team is happy to announce we have obtained our Health Canada certificate for the tremoFlo C-100. This is a proud moment for any Canadian medical device company, and we are excited to begin sales in Canada. Hospitals, clinics and research facilities across Canada can now offer effortless lung function measures to patients of all ages, including children as young as two years old.



Heidi Giesbrecht, Product Manager, said “to be certified in your home market is a great achievement. We look forward to working with all of our current and new customers in Canada. Next we will turn our attention to certification with the FDA in the coming months.”


[ Ask a Question | View Health Canada Certificate | Follow us on Twitter | Connect on LinkedIn ]

Monday, January 27, 2014

tremoFlo™ C-100 Airwave Oscillation System™ receives CE Mark

We are pleased to announce that on January 8, 2014, our tremoFlo C-100 Airwave Oscillometry System received its CE Mark as a class II medical device. This makes the tremoFlo C-100 the first and only approved handheld Oscillometry system for effortless lung function testing in Europe.

   

“The CE Mark is an important milestone on our regulatory and go-to-market roadmap,” says Thomas F. Schuessler, President and CEO of THORASYS Thoracic Medical Systems Inc. “I would like to thank all members of our excellent team for their dedication and hard work that has allowed us to reach this important milestone on schedule.” 

Europe is the first jurisdiction where the tremoFlo C-100 is authorized as a medical device to diagnose and monitor lung disease. Applications for regulatory approval are currently in progress in a variety of other jurisdictions, including Canada and the United States, and updates will be provided regularly on this blog. 

Thursday, September 13, 2012

Thorasys receives $500k investment from ACOA

We are pleased to announce that THORASYS Thoracic Medical Systems Inc. (THORASYS) has received an investment of $500,000 (Canadian Funds) under the Business Development Program (BDP) from the Atlantic Canada Opportunities Agency (ACOA). The funds will be used to help THORASYS with the final steps required to bring the tremoFlo™ Airwave Oscillometry System (AOS)™ to market in the next twelve months.

Public Announcement

The official announcement took place Wednesday, September 12th, at the Dalhousie University Life Sciences Research Centre located near the Innovacorp offices. Dr. Thomas Schuessler, President and CEO of THORASYS, accepted the award on behalf of the THORASYS team and thanked ACOA and the Government of Canada for their support through the BDP and other programs. The ACOA funding “will be used towards a variety of go-to-market activities, including regulatory approval, marketing activities and launch preparations”, Schuessler said, “as well as to build THORASYS’ distribution network”.
The funding announcement came just days after the European Respiratory Society (ERS) Congress in Vienna, Austria, where the tremoFlo was introduced for the first time on European soil and received an enthusiastic response. Potential distributors, clinicians and global key opinion leaders coming by the THORASYS booth were impressed by the tremoFlo’s form factor, portability, ease of use, and the minimum effort and cooperation required from the patient when compared to Spirometry.

Congratulations to DeNovaMed

We would like to take this opportunity to also congratulate Halifax-based DeNovaMed, who received similar funding for their ground-breaking work towards developing treatments for drug-resistant infectious diseases.
For media coverage of the ACOA announcement, refer to The Chronicle Herald and to the AllNovaScotia.com website (subscribers only). A news release from the Government of Canada is also available on the ACOA site.